tbuckley/cabot-search huggingface dataset:
Engraftment and molecular monitoring of CD34+ peripheral-blood stem-cell transplants for follicular lymphoma: a pilot study.
Authors: I G McQuaker, A P Haynes, S Anderson, C Stainer, R G Owen, G J Morgan, M Lumley, D Milligan, J Fletcher, E M Bessell, J M Davis, N H Russell
Journal: Journal of Clinical Oncology (1997)

PURPOSE A pilot study to validate the use of CD34+ selection (Ceprate SC) of blood stem-cell collection in patients with advanced follicular lymphoma receiving myeloablative chemoradiotherapy. PATIENTS AND METHODS Seventeen patients were entered onto the protocol. Thirteen of 17 patients have undergone transplantation; the median age is 42.5 years (range, 33 to 51), seven of 13 are stage IVB, two stage IVA, three stage IIIB, and one stage IIB. All except two patients were treated after first or subsequent relapses after receiving cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) chemotherapy to achieve a good partial (six of 13) or complete (seven of 13) response before stem-cell mobilization with cyclophosphamide 3 g/m2 and filgrastim 300 microg once daily. RESULTS Eleven of 13 patients had a detectable t(14;18) by nested polymerase chain reaction (PCR). Median CD34+ count before selection was 2.9 x 10(6)/kg (range, 1.17 to 11.3) and after CD34+ selection was 1.54 x 10(6)/kg (range, 0.88 to 7.6) with a median CD34+ yield of 62.4% (range, 17% to 95%) and purity of 60% (range, 39.3% to 73%). Of the 11 patients known to have t(14;18), 10 had PCR-detectable contamination of stem-cell harvests that became PCR negative in six of the 10 after CD34+ selection. Engraftment was rapid with a median day to absolute neutrophil count (ANC) greater than 0.5 x 10(9)/L of 13 days (range, 11 to 21) and platelet count greater than 20 x 10(9)/L of 14 days (range, 10 to 44). With a median follow-up duration of 15 months, three patients have remained persistently PCR-positive, two of whom received PCR-positive stem cells. Two have relapsed. Of the seven patients who received PCR-negative stem cells, five have had no PCR-detectable disease in posttransplant bone marrow samples. CONCLUSION Longer follow-up duration is required to determine the significance of these findings, but we have confirmed the feasibility of CD34+ selected cells to deplete peripheral-blood stem cells of tumor cells from patients undergoing high-dose therapy for follicular lymphoma.
p53 Gene Status and Response to Platinum/Paclitaxel-Based Chemotherapy in Advanced Ovarian Carcinoma
Authors: Cinzia Lavarino, Silvana Pilotti, Maria Oggionni, Laura Gatti, Paola Perego, Gianluigi Bresciani, Marco A. Pierotti, Giovanni Scambia, Gabriella Ferrandina, Anna Fagotti, Costantino Mangioni, Valeria Lucchini, Francesca Vecchione, Giorgio Bolis, Giovanna Scarfone, Franco Zunino
Journal: Journal of Clinical Oncology (2000)

PURPOSE: The p53 gene plays a critical role in cellular response to DNA damage and has been implicated in the response to platinum compounds in ovarian carcinoma patients. Because taxanes could induce p53-independent apoptosis, we assessed the relevance of p53 gene status to response in ovarian carcinoma patients receiving paclitaxel and platinum-containing chemotherapy. PATIENTS AND METHODS: Forty-eight previously untreated patients with advanced disease received standard paclitaxel/platinum-based chemotherapy. In tumor specimens collected at the time of initial surgery, before therapy, p53 gene status and expression were examined by single-strand conformation polymorphism, sequence analysis, and immunohistochemical analysis. Microsatellite instability analysis was performed on available samples from 30 patients. RESULTS: Thirty-four (71%) of the 48 patients had a clinical response. Pathologic complete remission was documented in 13 (27%) of 48 patients. p53 mutations were detected in 29 (60%) of 48 tumors. Among the patients with mutant p53 tumors, 25 patients (86%) responded to chemotherapy. Only nine (47%) of 19 patients with wild-type p53 tumors responded to the same treatment. The overall response rate and the complete remission rate were significantly higher among patients with mutant p53 tumors than among patients with wild-type p53 tumors (P = .008). Most of the tested tumors not associated with complete remission (10 of 12 tumors) were also characterized by microsatellite instability. The complete remission rate was higher among patients with tumors without microsatellite instability (five of seven patients). CONCLUSION: In contrast to the limited efficacy of treatment with paclitaxel in combination with standard platinum doses against wild-type p53 ovarian tumors, patients with mutant p53 ovarian tumors were more responsive to paclitaxel-based chemotherapy. The pattern of response to chemotherapy containing paclitaxel is different from that associated with high-dose cisplatin therapy. Determining p53 mutational status can be useful in predicting therapeutic response to drugs effective in ovarian carcinoma.
Daily physical activity in patients with COPD living alone or not: Preliminary results
Authors: Nidia A. Hernandes, Thaís Sant'Anna, Carlos A. Camillo, Anaísa C. Verceze, Victoria C. Escobar, Vanessa S. Probst, Fabio Pitta
Journal: European Respiratory Journal (2011)

Background:  Although patients with chronic obstructive pulmonary disease (COPD) are known to be physically inactive, we hypothesized that those living alone are less inactive in daily life than patients living with family in order to maintain their functional needs.   Objective:  To compare the physical activities in daily life between patients with COPD either living alone or with their families.   Methods:  Physical activities in daily life were evaluated in 10 patients living alone (4 male, 64 [61-68] years, FEV 1  39 [26-62]%pred, BMI 23 [21-30] kg m -2 ) and 10 paired patients living with their families (4 male, 66 [61-71] years, FEV 1  41 [30-49]%pred, BMI 22 [20-29] kg m -2 ) using a multiaxial accelerometer (MiniMod, McRoberts, the Netherlands) during 12 hours/day for two consecutive weekdays. Other measurements were: spirometry, respiratory and peripheral muscle force (maximal respiratory pressures [MIP and MEP] and quadriceps one-repetition maximum test [1RM], respectively) and functional exercise capacity (6-minute walk test, 6MWT).   Results:  The two groups had similar 6MWT, MIP, MEP and quadriceps 1RM. Time spent walking/day was 71 [37-112] min/day in patients living alone and 49 [19-80] min/day in patients living with their families (p=0.129). Moreover, patients living with their families tended to spend more time lying/day (143 [112-244] vs. 87 [48-177] min/day, p=0.093).   Conclusion:  These preliminary results suggest that patients with COPD living alone are more active in daily life than patients living with their families, despite presenting similar functional exercise capacity and muscle force. This might implicate in a different treatment approach in patients living alone or with family.
From the Serotonin Model of Suicide to a Mental Pain Model of Suicide
Authors: Jose de Leon, Enrique Baca-García, Hilario Blasco-Fontecilla
Journal: Psychotherapy and Psychosomatics (2015)

After the first article on suicide attempts [10] , the first author, influenced by the prevailing environment, advised his young mentee (the second author) that he needed to focus on biological factors, such as hormones and genes in the context of the serotonin model of SB, and on suicide attempters, who were much easier to study in a clinical setting than suicide completers.
LATE BREAKING CLINICAL TRIAL (JCS 2015) : Multicenter, Randomized, Double-Blinded, Placebo-Controlled Phase II Study of Serelaxin in Japanese Patients With Acute Heart Failure
Authors: Naoki Sato, Wataru Takahashi, Atsushi Hirayama, Masayoshi Ajioka, Naoto Takahashi, Kaoru Okishige, XingLi Wang, Akio Maki, Hideki Maruyama, Ursula Ebinger, Masayuki Yamaguchi, Yinuo Pang, Hiroki Matsumoto, Masatoshi Kawana
Journal: Circulation (2015)
Survival outcomes in advance non-small cell lung cancer – A developing country scenario
Authors: Randeep Guleria, Anant Mohan, Sachin Kumar, Ashraf Ali, Ajeet Kumar
Journal: European Respiratory Journal (2011)

Background:  Lung cancer is common and has poor survival outcome. Chemotherapy provides modest improvement. Many patients can not afford chemotherapy and it utility in advanced lung cancer in resource limited setting is debatable.Our goal was to assess the effect of chemotherapy on survival   Method:  78 cases with advanced Non Small Cell Lung Cancer were followed up. All cases were offered platinum based chemotherapy. Patient characteristics, staging and performance status was noted. Chemotherapy arm was compared with the group not willing for chemotherapy for mortality and other parameters. Relevant statistical analysis was done. Kaplan-Meir survival estimates was generated.   Results:  41 patients received chemotherapy and 37 patients did not receive chemotherapy. The 2 groups were well matched.  Results of Kaplan-Meir analysis are shown.   Conclusion:  In advanced lung cancer patients a platinum based chemotherapy provided a significant survival advantage and should be advised to these patients even in a resource limited setting.
Phase I clinical trial of namitecan (ST1968): Results with D1-3 q3wks schedule.
Authors: A. Fasolo, G. Del Conte, R. G. Calderone, E. Gallerani, N. Hagner, P. Barbieri, L. Luraghi, S. Pace, F. Capocasa, N. Coceani, E. Maccioni, D. Hess, C. Sessa, L. Gianni
Journal: Journal of Clinical Oncology (2011)

e13570 Background: Namitecan (N) is a topoisomerase I inhibitor with superior antitumor activity (especially in squamous cell ca., SCC) and a more favourable safety profile than irinotecan and topotecan. Pharmacokinetic (PK) studies in repeated dosing schedule (schd) showed a lack of metabolites production and no accumulation due to short half life. In first phase I studies, N was given as 2 hours iv infusion, flat dose: the recommended doses (RD) with D1, D8 q3wks and D1 q3wks schd were 15 and 23 mg, respectively. A D1-3 q3wks schd in patients (pts) with advanced solid tumors was evaluated to increase tumor exposure. Methods: Based on available PK and safety profile, the starting dose was 7 mg iv D1-3 q3wks, corresponding to an estimated D3 AUCINF of 11,850 hr*ng/mL as PK simulation from the RD of 15 mg of D1, D8 schedule. Dose escalation followed a toxicity based 3+3 cohort design. Dose-limiting toxicities (DLTs) were: ANC G4 for >5 days; febrile neutropenia; PLT ≥ G3; liver/renal toxicity ≥ G2 not recovered by D22; non-hematologic toxicity ≥ G3 (CTCAE v.3.0); delay of cycle 2 > 2 weeks (wks). PK evaluations were performed on D1, 3, 4, 5 and 11 of cycle 1. Results: So far 16 pts (7 H&N, 4 CRC, 5 others) have been treated; at 7 mg 3/6 pts experienced DLTs (2 ANC G4 > 5 days; 1 PLT G3) and the lower dose level (5 mg) has been evaluated in 9 pts with no DLTs. Next dose level will be 6 mg. ANC ≥ G3 occurred in all pts at 7 mg (median time to nadir 15 days, with recovery in <1 wk). Other toxicities were mild to moderate asthenia, nausea and vomiting. One pt with bladder carcinoma achieved a PR lasting 10+ months (mos); SD ≥ 4 mos were reported in 4 pts (endometrium, CRC, H&N and cervix ca.). As expected from PK simulation, the mean D3 AUCINF was 10700 hr*ng/mL at 7mg dose. N was linearly and proportionally related to the administered dose, being its clearance independent from plasma concentration. Due to its long half life (40-45 hr) N accumulated in plasma by a factor of 1.6 over the 3 day dosing. Conclusions: The present study confirms the safety and PK profile of N. Promising preclinical data, manageable neutropenia and hints of antitumor activity with objective response in bladder and endometrium ca support further clinical development of the compound.
Complications of 1303 Central Venous Cannulations
Authors: A Yilmazlar, H Bilgin, G Korfali, A Eren, U Özkan
Journal: Journal of the Royal Society of Medicine (1997)

Central venous catheterization (CVC), now a common procedure, has several major complications. We assessed their incidence in a prospective study of 1303 cannulations done in the intensive care unit or operating theatre. Chest radiographs were obtained to verify proper catheter placement and to detect pneumothorax. Complications were arterial puncture in 68 (5.2%) patients, arrhythmias in 21 (1.6%), cardiopulmonary arrest in 1 (0.1%), and pneumothorax in 5 (0.5%). The tip of the CVC was incorrectly located in 149 (11.2%). The chest radiograph was a valuable method for detecting complications of central venous catheterization.
Phase II study of subcutaneous interleukin-2 in unselected patients with advanced renal cell cancer on an outpatient basis.
Authors: D T Sleijfer, R A Janssen, J Buter, E G de Vries, P H Willemse, N H Mulder
Journal: Journal of Clinical Oncology (1992)

PURPOSE A single-institution phase II study was undertaken to evaluate the efficacy and toxicity of interleukin-2 (IL-2) administered by subcutaneous injection. PATIENTS AND METHODS Twenty-seven unselected patients (15 male) with a mean age of 60 years (range, 42 to 76 years) who had advanced renal cell cancer were treated as outpatients. IL-2 was given once a day, 5 days per week for 6 weeks. During the first 5-day cycle, 18 x 10(6) IU was given once daily; in the following cycles, the doses in the first 2 days were reduced to 9 x 10(6) IU. After a 3-week rest period, treatment was repeated in patients who had a response or stable disease (SD). To prevent pyretic reactions, patients also received acetaminophen (250 to 500 mg given orally every 4 to 6 hours). RESULTS After 6 weeks, 26 patients were assessable for response. Two patients (8%) had a complete remission (CR), four (15%) had a partial remission (PR), and 13 (50%) had SD. A second cycle of 6 weeks was given to 19 patients; one patient with a PR and six with SD showed progression. Duration of the CR was 17+ and 19+ months, and length of the PR was 2, 8, 11, and 11+ months. The median survival of the patients who were nonresponders and responders was 10 and 20+ months, respectively, and for all patients was 13 months. One patient died as a result of myocardial infarction and brain stem ischemia. Systemic side effects in the other patients were tolerated and accepted, and included transient inflammation and local induration at the injection sites, fever and chills, and nausea. CONCLUSION Subcutaneous IL-2 is clinically active, has an acceptable toxicity, and can be given to patients with concomitant disease.
Sym004: Truly a New Level of Anti-EGFR Treatment?
Authors: Sebastian Stintzing, Volker Heinemann
Journal: Cancer Discovery (2015)

Abstract Summary: Sym004 is a new antibody mixture to target EGFR in metastatic colorectal cancer. Preclinical data suggest efficacy in anti–EGFR-resistant tumors, but it remains unclear whether a higher toxicity is outweighed by those advantages. Cancer Discov; 5(6); 578–80. ©2015 AACR. See related article by Dienstmann and colleagues, p. 598.
RUNX3, A Novel Tumor Suppressor, Is Frequently Inactivated in Gastric Cancer by Protein Mislocalization
Authors: Kosei Ito, Qiang Liu, Manuel Salto-Tellez, Takashi Yano, Kotaro Tada, Hiroshi Ida, Canhua Huang, Nilesh Shah, Masafumi Inoue, Andrea Rajnakova, Kum Chew Hiong, Bee Keow Peh, Hwan Chour Han, Tomoko Ito, Ming Teh, Khay Guan Yeoh, Yoshiaki Ito
Journal: Cancer Research (2005)

Loss of RUNX3 expression is suggested to be causally related to gastric cancer as 45% to 60% of gastric cancers do not express RUNX3 mainly due to hypermethylation of the RUNX3 promoter. Here, we examined for other defects in the properties of RUNX3 in gastric cancers that express RUNX3. Ninety-seven gastric cancer tumor specimens and 21 gastric cancer cell lines were examined by immunohistochemistry using novel anti-RUNX3 monoclonal antibodies. In normal gastric mucosa, RUNX3 was expressed most strongly in the nuclei of chief cells as well as in surface epithelial cells. In chief cells, a significant portion of the protein was also found in the cytoplasm. RUNX3 was not detectable in 43 of 97 (44%) cases of gastric cancers tested and a further 38% showed exclusive cytoplasmic localization, whereas only 18% showed nuclear localization. Evidence is presented suggesting that transforming growth factor-beta is an inducer of nuclear translocation of RUNX3, and RUNX3 in the cytoplasm of cancer cells is inactive as a tumor suppressor. RUNX3 was found to be inactive in 82% of gastric cancers through either gene silencing or protein mislocalization to the cytoplasm. In addition to the deregulation of mechanisms controlling gene expression, there would also seem to be at least one other mechanism controlling nuclear translocation of RUNX3 that is impaired frequently in gastric cancer.
Abstract 16275: Increased Expression of NANOG Induces the Transitioning of Endothelial Cells into a Stem-Like State
Authors: Erin E Kohler, Jugajyoti Baruah, Asrar Malik, Kishore K Wary
Journal: Circulation (2011)

RATIONALE: Given that NANOG binds to and activates the FLK-1 (Fetal Liver Kinase-1) receptor to induce proliferation and angiogenesis in endothelial cells (ECs), increased expression of NANOG may s...
Calbindin-D9k and parvalbumin are exclusively located along basolateral membranes in rat distal nephron.
Authors: R J Bindels, J A Timmermans, A Hartog, W Coers, C H van Os
Journal: Journal of the American Society of Nephrology (1991)

There is strong evidence that vitamin D-dependent Ca(2+)-binding proteins, i.e., calbindin-D9k and calbindin-D28k, facilitate diffusion of Ca2+ through the cytosolic compartment of renal and intestinal cells, which transport Ca2+ transcellularly. In the study presented here, parvalbumin, calbindin-D9k, and calbindin-D28k were localized precisely by immunocytochemistry in rat kidney. Antisera recognizing specifically the thick ascending loop of Henle, the connecting tubules and collecting ducts, and the intercalated cells of the collecting ducts were used to identify different cell types. In rat kidney cortex, parvalbumin and calbindin-D9k colocalized in the thick ascending loop of Henle, the distal convoluted tubule, the connecting tubule, and the intercalated cells of the collecting duct. Strikingly, in all responsive cells, parvalbumin and calbindin-D9k were exclusively present in a thin layer along the basolateral membrane. In contrast, calbindin-D28k was only present in the distal convoluted and connecting tubule, where it was evenly distributed through the cytosol. In conclusion, the exclusive localization of parvalbumin and calbindin-D9k at the basolateral membrane of immunopositive renal cells implies their involvement in the regulation of transport processes located in these membranes rather than a role as intracellular Ca2+ buffer and Ca2+ shuttle between the two opposing membranes.
Vascular Liver Tumors Induced in &lt;italic&gt;Mastomys(Praomys) natalensis &lt;/italic&gt; by Single or twofold administration of DimethyInitrosamine
Authors: K Wayss, P Bannasch, J Mattern, M Volm
Journal: JNCI Journal of the National Cancer Institute (1979)

Administration of dimethylnitrosamine (DMNA) to Mastomys (Praomys) natalensis made it possible to induce vascular tumors of the liver and follow all stages of tumor development. At the age of 5 weeks, male and female animals received 10 mg DMNAlkg body weight once or 5 mg DMNA/kg body weight twice, Injected ip (dose/animal: ≈0.35 mg in males, and ≈0.25 mg in females). They were killed 35, 41, 47, and 55 weeks after application of the carcinogen. Of 173 experimental animals, 164 (95%) developed benign hemangloendothellomas and 10 developed malignant hemangloendothellomas in addition. The benign hemangloendothellomas were characterized by solitary or multiple distended blood lacunae. Macroscopically, they resembled pellosls hepatis. The distended blood lacunae were frequently thrombosed. The coating endothelium appeared only slightly altered (Inconstant nuclear enlargement) under the light microscope. Focal sinus dilatations were regarded as early stages of these tumors. In advanced stages, entire liver lobes could be interspersed by a diffuse hemangloendothellomatosls. In addition, tumor formations were occasionally found that resembled the cavernous hemangioma in man. Rupture of the hemangloendothellomas often gave rise to hemorrhaging into the abdominal cavity. In contrast to the benign hemangloendothellomas, the hemangiosarcomas, which appeared in later stages of the experiments, showed a pronounced proliferation of atypical sinus wall cells with pronounced polymorphism of cells and nuclei. In isolated cases, the sarcomas metastasized into the lungs and adrenal cortex. Most hemangiosarcomas were close to benign hemangloendothellomas. The possibility of a transition from benign to malignant hemangloendothellomas was examlned
Phase II study of coumarin and cimetidine in patients with metastatic renal cell carcinoma.
Authors: F H Dexeus, C J Logothetis, A Sella, K Fitz, R Amato, J M Reuben, N Dozier
Journal: Journal of Clinical Oncology (1990)

Fifty patients with locally advanced or metastatic renal cell carcinoma were treated with coumarin (1,2-benzopyrone) at 100 mg orally daily starting on day 1 and cimetidine 300 mg orally four times a day starting on day 15. When disease progressed, coumarin was escalated to 100 mg orally four times a day. Three patients (6%; 95% confidence interval [Cl], 2% to 17%) achieved a partial response, one of those after dose escalation. In addition, one patient had a minor response, then progressing disease, and again had a minor response after dose escalation. All four responders had nonassessable primary tumors (three had had prior nephrectomy and one a renal angioinfarction). The only major toxicity was renal (37 patients had minor to moderate elevations in serum creatinine level). Immunologic studies (hypersensitivity skin testing, lymphocyte blastogenesis response, number of lymphocytes, T lymphocytes, T helper and T suppressor subsets, and T helper: suppressor ratio), performed before and after therapy, showed a relative lymphopenia and decreased hypersensitivity skin-testing results at baseline, and a general decline over time in the number of T cells and T helper and T suppressor subsets. There was no enhancement in any of the immunologic parameters tested. The response rate was 6%, lower than previously reported; a general immunodeficiency was noted at baseline, and the lymphopenia worsened with progressing disease, unaffected by therapy.
Does music affect fatigue perception during exercise in COPD patients
Authors: Gregory Reychler, Caroline Clerens, Stéphane Fizaine, Emmanuelle Wasterlain, Thibault Coppens, Boland Maelle, Thierry Pieters, Gilles Caty, Giuseppe Liistro
Journal: European Respiratory Journal (2012)

Introduction: Performing daily life activities is difficult for many COPD patients. Pulmonary rehabilitation (PR) is useful to improve exercise tolerance. If dyspnoea remains the primary debilitating symptom associated with COPD, fatigue is also frequent in patients suffering from lung disease, especially during and after physical activities. Influence of music on dyspnoea was previously reported. The aim of this preliminary study was to observe the influence of music on fatigue during pulmonary rehabilitation sessions.

Material and Method: 12 COPD patients regularly attending our PR program were recruited (age=63.9 y.o. ± 13.0). Fatigue was measured during two sessions by a questionnaire comprising 8 items. Investigation was performed during two separate sessions with or without music. PR exercises were the same during both sessions.

Results: There was no difference in total fatigue score (16.7 ± 4.7 vs 17.1 ± 5.0; p = 0.58). The 8 items were not different between both sessions. Except for two items, all questions were well correlated between the two sessions.

Conclusion: In this preliminary study, we have shown that music does not influence fatigue perception during a PR session.